Clitoral Reconstruction (CR) in FGM/C Patients
Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · Aug 24, 2021
Trial Information
Current as of May 30, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Signed informed consent of the present study
- • French and / or English speaking
- Exclusion Criteria:
- • Insufficient knowledge of project language (French/English)
- • No informed consent
- • Inability to sign consent
About University Hospital, Basel, Switzerland
The University Hospital Basel, Switzerland, is a leading academic medical center renowned for its commitment to cutting-edge research and innovative patient care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise and state-of-the-art facilities to advance medical knowledge and therapeutic options across various disciplines. With a collaborative approach that integrates clinical practice and scientific inquiry, the University Hospital Basel fosters an environment conducive to rigorous clinical trials, ensuring the highest standards of safety and efficacy. Its strategic focus on patient-centered research aims to translate scientific discoveries into tangible health solutions, benefiting both local and global communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Genève, , Switzerland
Patients applied
Trial Officials
Jasmine Abdulcadir, PD Dr. med.
Principal Investigator
Department of Obstetrics and Gynecology, University Hospital of Geneva (HUG)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials